Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AWHNASDAQ:CARMNASDAQ:DWTXNASDAQ:MBRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAWHAspira Women's Health$0.08-12.5%$0.08$0.08▼$1.73$2.44M2.011.53 million shs4.31 million shsCARMCarisma Therapeutics$0.40-2.0%$0.31$0.14▼$1.38$16.84M1.923.71 million shs487,747 shsDWTXDogwood Therapeutics$4.60-4.2%$5.02$1.62▼$29.28$9.17M1.81.51 million shs27,415 shsMBRXMoleculin Biotech$0.39+14.4%$0.74$0.25▼$4.71$4.80M1.381.94 million shs3.94 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAWHAspira Women's Health0.00%0.00%0.00%-9.89%-92.61%CARMCarisma Therapeutics-2.71%+0.87%+103.71%+124.43%-65.65%DWTXDogwood Therapeutics-4.56%-3.56%-5.93%+27.42%+459,999,900.00%MBRXMoleculin Biotech+11.09%+28.78%-41.97%-47.32%-88.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAWHAspira Women's Health0.9049 of 5 stars3.50.00.00.00.00.00.0CARMCarisma Therapeutics2.3525 of 5 stars3.22.00.00.02.91.70.6DWTXDogwood Therapeutics1.1333 of 5 stars3.50.00.00.00.00.00.6MBRXMoleculin Biotech3.1401 of 5 stars3.52.00.00.03.41.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAWHAspira Women's Health 3.00Buy$5.506,607.32% UpsideCARMCarisma Therapeutics 2.43Hold$1.93387.34% UpsideDWTXDogwood Therapeutics 3.00Buy$10.00117.39% UpsideMBRXMoleculin Biotech 3.00Buy$4.00928.81% UpsideCurrent Analyst Ratings BreakdownLatest AWH, CARM, MBRX, and DWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/9/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$4.004/23/2025DWTXDogwood TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAWHAspira Women's Health$9.18M0.27N/AN/A($0.23) per share-0.36CARMCarisma Therapeutics$19.63M0.84N/AN/A($0.67) per share-0.59DWTXDogwood TherapeuticsN/AN/AN/AN/A($7.56) per shareN/AMBRXMoleculin BiotechN/AN/AN/AN/A$1.77 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAWHAspira Women's Health-$16.69M-$0.98N/A∞N/A-165.07%N/A-267.23%8/11/2025 (Estimated)CARMCarisma Therapeutics-$60.48M-$1.56N/AN/AN/A-254.28%N/A-137.38%8/6/2025 (Estimated)DWTXDogwood Therapeutics-$12.35M-$18.04N/AN/AN/AN/AN/A-34.74%8/6/2025 (Estimated)MBRXMoleculin Biotech-$21.76MN/A0.00N/AN/AN/A-278.80%-100.11%8/4/2025 (Estimated)Latest AWH, CARM, MBRX, and DWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CARMCarisma Therapeutics-$0.17-$0.22-$0.05-$0.22$2.47 million$3.65 million5/13/2025Q1 2025MBRXMoleculin Biotech-$0.71-$0.69+$0.02-$0.69N/AN/A5/8/2025Q1 2025DWTXDogwood Therapeutics-$0.77-$4.21-$3.44-$8.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAWHAspira Women's Health$1.041,268.29%N/AN/A N/ACARMCarisma TherapeuticsN/AN/AN/AN/AN/ADWTXDogwood TherapeuticsN/AN/AN/AN/AN/AMBRXMoleculin BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAWHAspira Women's HealthN/A0.750.70CARMCarisma TherapeuticsN/A1.341.34DWTXDogwood TherapeuticsN/A7.437.43MBRXMoleculin BiotechN/A1.351.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAWHAspira Women's Health12.19%CARMCarisma Therapeutics44.27%DWTXDogwood Therapeutics9.05%MBRXMoleculin Biotech15.52%Insider OwnershipCompanyInsider OwnershipAWHAspira Women's Health4.30%CARMCarisma Therapeutics12.57%DWTXDogwood Therapeutics3.90%MBRXMoleculin Biotech1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAWHAspira Women's Health11029.76 million16.92 millionNo DataCARMCarisma Therapeutics2041.79 million36.54 millionNo DataDWTXDogwood Therapeutics51.91 million1.84 millionN/AMBRXMoleculin Biotech2014.13 million13.86 millionNot OptionableAWH, CARM, MBRX, and DWTX HeadlinesRecent News About These CompaniesSeveral Insiders Invested In Moleculin Biotech Flagging Positive NewsJuly 4, 2025 | finance.yahoo.comMoleculin Biotech Faces Nasdaq Delisting WarningJune 27, 2025 | tipranks.comMBRX Moleculin Biotech, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comMoleculin Biotech, Inc. (NASDAQ:MBRX) CFO Acquires $99,999.90 in StockJune 24, 2025 | insidertrades.comMoleculin Gets Positive FDA Feedback On Pediatric Study Plan For Annamycin In Children With R/R AMLJune 20, 2025 | nasdaq.comMoleculin Biotech prices $5.9M public offering; shares down about 47%June 20, 2025 | msn.comMoleculin Biotech, Inc. Announces Pricing of $5.9 Million Public Offering of Common Stock and Series E WarrantsJune 20, 2025 | quiverquant.comQMoleculin Announces $5.9 Million Public OfferingJune 20, 2025 | globenewswire.comMoleculin Biotech, Inc.: Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AMLJune 18, 2025 | finanznachrichten.deMoleculin Biotech, Inc. Advances Annamycin for Pediatric Cancer Treatment as FDA Approves Inclusion of Younger Patients in Clinical StudyJune 18, 2025 | quiverquant.comQMoleculin Participates in Virtual Investor “What This Means” SegmentJune 18, 2025 | globenewswire.comMoleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AMLJune 18, 2025 | globenewswire.comMoleculin Biotech announces ‘What This Means’ virtual investor segmentJune 12, 2025 | finance.yahoo.comMoleculin Biotech, Inc. Reports Positive Topline Results from Phase 1B/2 Trial of Annamycin for Soft Tissue Sarcoma Lung MetastasesJune 11, 2025 | quiverquant.comQMoleculin Participates in Virtual Investor “What This Means” SegmentJune 11, 2025 | globenewswire.comMoleculin Biotech Hosts Key Opinion Leaders EventJune 5, 2025 | tipranks.comMoleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)June 5, 2025 | globenewswire.comMoleculin Biotech Reports Positive Annamycin Trial ResultsJune 4, 2025 | msn.comMoleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)June 4, 2025 | globenewswire.comMoleculin Biotech files to sell 10.99M shares of common stock, warrantsJune 2, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAWH, CARM, MBRX, and DWTX Company DescriptionsAspira Women's Health NASDAQ:AWH$0.08 -0.01 (-12.49%) As of 04/16/2025Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.Carisma Therapeutics NASDAQ:CARM$0.40 -0.01 (-1.99%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$0.40 +0.01 (+1.27%) As of 07/7/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.Dogwood Therapeutics NASDAQ:DWTX$4.60 -0.20 (-4.17%) As of 07/7/2025 03:59 PM EasternDogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.Moleculin Biotech NASDAQ:MBRX$0.39 +0.05 (+14.35%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$0.43 +0.04 (+10.85%) As of 07/7/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
